The U.S. Food and Drug Administration Approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Direct-acting […]
This post first appeared on AuroBlog - The Official Blog Of Aurous HealthCare CRO, please read the originial post: here